CNDIF

CANADIAN IMPERIAL BANK OF COMMERCE /CAN/

OTC · Commercial Banks, NEC · CIK 0001045520

$0.4500 -3.35%

High Impact Filing (7/10)

Vol

SEC Reports15

Exchange OTC·Sector Commercial Banks, NEC·CIK 0001045520·Prev Close $0.4656

Recent Activity

Jun 5, 2026 SEC

CIBC filed a routine 6-K furnishing CEO and CFO certifications under Rules 13a-14/15d-14 and Section 906 of the Sarbanes

6-K — Impact 2/10

Jun 5, 2026 SEC

Canadian Imperial Bank of Commerce's shelf registration (File No. 333-294072) on Form F-3 was declared effective by the

EFFECT — Impact 3/10

Jun 4, 2026 SEC

Canadian Imperial Bank of Commerce filed a 424B5 product supplement for Autocallable Strategic Accelerated Redemption Se

424B5 — Impact 3/10

Latest Reports

NEUTRAL 6-K 2/10

CIBC filed a routine 6-K furnishing CEO and CFO certifications under Rules 13a-14/15d-14 and Section 906 of the Sarbanes

NEUTRAL EFFECT 3/10

Canadian Imperial Bank of Commerce's shelf registration (File No. 333-294072) on Form F-3 was declared effective by the

∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

15 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 13 neutral. Avg impact: 3.3/10.

NEUTRAL 6-K 2/10

CIBC filed a routine 6-K furnishing CEO and CFO certifications under Rules 13a-14/15d-14 and Section

NEUTRAL EFFECT 3/10

Canadian Imperial Bank of Commerce's shelf registration (File No. 333-294072) on Form F-3 was declar

NEUTRAL 424B5 3/10

Canadian Imperial Bank of Commerce filed a 424B5 product supplement for Autocallable Strategic Accel

NEUTRAL 424B5 3/10

Canadian Imperial Bank of Commerce filed a 424B5 product supplement for Accelerated Return Notes (AR

NEUTRAL 424B5, 6-K 4/10

CIBC filed a 424B5 product supplement for Senior Global Medium-Term Notes linked to equity indices,

NEUTRAL 424B5 2/10

CIBC filed a 424B5 product supplement (No. WF-1) under its existing shelf registration (333-294072)

NEUTRAL 424B5 2/10

CIBC filed a 424B5 ETF Underlying Supplement establishing a shelf program for issuing senior unsecur

NEUTRAL 424B5 2/10

CIBC filed a 424B5 prospectus supplement (Stock-Linked Underlying Supplement) establishing a program

NEUTRAL 424B5 2/10

CIBC filed an Equity Index Underlying Supplement (424B5) under its existing shelf registration (333-

NEUTRAL 424B5 3/10

CIBC filed a 424B5 prospectus supplement for its US$20 billion Senior Global Medium-Term Note progra

NEUTRAL 6-K 4/10

CIBC announced its intention to repurchase up to 30 million common shares (approximately 3.3% of out

NEUTRAL 6-K 3/10

CIBC announced senior executive leadership changes effective May 28, 2026, including the appointment

NEUTRAL 6-K 3/10

CIBC filed a Form 6-K with an exhibit disclosing its earnings coverage ratio on subordinated indebte

BULLISH 6-K 7/10

CIBC reported Q2 FY2026 results with reported net income of $2,465M (+23% YoY), revenue of $8,006M (

BULLISH 6-K 7/10

CIBC reported strong Q2 2026 earnings with revenue of $8,006 million (+14% YoY), reported net income

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Next Q	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Current FY	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Next FY	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

∅

No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.